Show simple item record

dc.contributor.authorMinniti, G
dc.contributor.authorBrada, M
dc.date.accessioned2018-08-30T13:48:33Z
dc.date.issued2007-11
dc.identifier8
dc.identifier.citationARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA, 2007, 51 pp. 1373 - 1380
dc.identifier.issn0004-2730
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2457
dc.identifier.doi10.1590/S0004-27302007000800024
dc.description.abstractPatients with residual or recurrent Cushing’s disease receive external beam radiotherapy (RT) with the aim of achieving long-term tumour control and normalization of elevated hormone levels. Treatment is given either as conventional radiotherapy using conformal techniques or as stereotactic radiotherapy, which is either used as fractionated treatment (SCRT) or as single fraction radiosurgery (SRS). We describe the technical aspects of treatment and report a systematic review of the published literature on the efficacy and toxicity of conventional RT, SCRT and SRS. There are no studies directly comparing the different radiation techniques and the reported results are inevitably of selected patients by investigators with interest in the treatment tested. Nevertheless the review of the published literature suggests better hormone and tumour control rates after fractionated irradiation compared to single fraction radiosurgery. Hypopituitarism represents the most commonly reported late complication of radiotherapy seen after all treatments. Although the incidence of other late effects is low, the risk of radiation injury to normal neural structures is higher with single fraction compared to fractionated treatment. Stereotactic techniques offer more localized irradiation compared with conventional radiotherapy, however longer follow-up is necessary to confirm the potential reduction of long-term radiation toxicity of fractionated SCRT compared to conventional RT. On the basis of the available literature, fractionated conventional and stereotactic radiotherapy offer effective treatment for Cushing’s disease not controlled with surgery alone. The lower efficacy and higher toxicity of single fraction treatment suggest that SRS is not the appropriate therapy for the majority of patients with Cushing’s disease.
dc.format.extent1373 - 1380
dc.languageeng
dc.language.isoeng
dc.publisherSBEM-SOC BRASIL ENDOCRINOLOGIA & METABOLOGIA
dc.titleRadiotherapy and radiosurgery for Cushing’s disease
dc.typeJournal Article
rioxxterms.versionofrecord10.1590/S0004-27302007000800024
rioxxterms.licenseref.startdate2007-11
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfARQUIVOS BRASILEIROS DE ENDOCRINOLOGIA E METABOLOGIA
pubs.notesaffiliation: Brada, M (Reprint Author), Inst Canc Res, Neurooncol Unit, Downs Rd, Sutton SM2 5PT, Surrey, England. Brada, Michael, Inst Canc Res, Neurooncol Unit, Sutton SM2 5PT, Surrey, England. Brada, Michael, Royal Marsden NHS Fdn Trust, Acad Unit Radiotherapy & Oncol, Sutton SM2 5PT, Surrey, England. Minniti, Giuseppe, NEUROMED Inst, Neuroendocrinol Unit, Dept Neurol Sci, Pozzilli, IS, Italy. keywords: fractionated stereotactic radiotherapy; pituitary adenomas; Cushing’s disease; radiosurgery; toxicity keywords-plus: GAMMA-KNIFE RADIOSURGERY; TERM-FOLLOW-UP; NONFUNCTIONING PITUITARY-ADENOMAS; FRACTIONATED STEREOTACTIC RADIOTHERAPY; RADIATION-THERAPY; NELSONS-SYNDROME; TRANSSPHENOIDAL SURGERY; BILATERAL ADRENALECTOMY; CONFORMAL RADIOTHERAPY; CONSERVATIVE SURGERY author-email: [email protected] number-of-cited-references: 52 times-cited: 18 usage-count-last-180-days: 0 usage-count-since-2013: 1 journal-iso: Arq. Bras. Endocrinol. Metabol. doc-delivery-number: 307UP unique-id: ISI:000256344300024 oa: gold_or_bronze da: 2018-08-30
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume51en_US
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record